Eckert & Ziegler Launches Actinium-225 Production Driving Radiopharmaceutical Innovation

Eckert & Ziegler Radiopharma GmbH has announced the successful launch of Actinium-225 (Ac-225) production, addressing a global shortage of this essential radionuclide. This achievement marks a collaborative effort with the Nuclear Physics Institute of the Czech Academy of Sciences (ÚJF). It confirms the effectiveness of the selected production technology and is also appropriate to attain the anticipated product parameters.

Alongwith with production, Eckert & Ziegler has begun the validation process to manufacture GMP-grade Ac-225, which is crucial for clinical applications and commercial use. The GMP-grade material is anticipated to be available by mid of 2025, opening new opportunities for pharmaceutical companies developing alpha-emitting radiopharmaceuticals.

 Dr. Lutz Helmke, Managing Director of Eckert & Ziegler Radiopharma GmbH, said this in a statement, “This milestone underscores our commitment to advancing cancer treatment through the reliable supply of radioisotopes. The commencement of Ac-225 production not only addresses the current shortage but also fortifies Eckert & Ziegler position as a key player in the future of radioligand therapy.”

The production facility utilises cutting-edge cyclotron technology to produce Ac-225 from Radium-226, representing a significant advancement in isotope production. ÚJF’s extensive expertise in nuclear research and radiopharmaceuticals was instrumental in designing and optimising this production pathway. Additionally, custom-engineered solutions from Isotope Technologies Dresden GmbH, part of Eckert & Ziegler’s hot cell division, contribute to the process’s efficiency and sustainability.

With the launch of Ac-225 production, Eckert & Ziegler strengthens its position as a leader in the evolving radiopharmaceutical industry, providing a scalable and reliable supply of Ac-225 for clinical trials and commercial manufacturing.